Revolutionizing Myeloma Care: AI Matches Patients to Trials | Jorge Hurtado Martinez, MD | EHA 2025

Revolutionizing Myeloma Care: AI Matches Patients to Trials | Jorge Hurtado Martinez, MD | EHA 2025
Revolutionizing Myeloma Care: AI Matches Patients to Trials | Jorge Hurtado Martinez, MD | EHA 2025
Belantamab Mafodotin in the Real World: Promising Myeloma Data | Fredrik Schjesvold, MD, PhD | #EHA2025
Belantamab Mafodotin in the Real World: Promising Myeloma Data | Fredrik Schjesvold, MD, PhD | #EHA2025
CONCEPT Trial | Isa-KRd : New Hope for High-Risk Myeloma Patients | Lisa Leypoldt, MD | #EHA2025
CONCEPT Trial | Isa-KRd : New Hope for High-Risk Myeloma Patients | Lisa Leypoldt, MD | #EHA2025
ADVANCE Trial | Dara‑KRd in NDMM yields ~ 60% MRD‑Negativity| Ola Landgren, MD, PhD- #EHA25 #myeloma
ADVANCE Trial | Dara‑KRd in NDMM yields ~ 60% MRD‑Negativity| Ola Landgren, MD, PhD- #EHA25 #myeloma
IRAKLIA Trial: On-Body Subcutaneous Isatuximab Delivery in Myeloma | Muhamed Baljevic, MD | #EHA2025
IRAKLIA Trial: On-Body Subcutaneous Isatuximab Delivery in Myeloma | Muhamed Baljevic, MD | #EHA2025
HDP‑101: Promising Anti‑BCMA ADC with Novel Payload for Myeloma | Shambavi Richard, MD | EHA 2025
HDP‑101: Promising Anti‑BCMA ADC with Novel Payload for Myeloma | Shambavi Richard, MD | EHA 2025
Circulating Tumor Cells- Non-Invasive Biomarker for Staging Myeloma | Luca Bertamini, MD | #EHA2025